| 2.09 0.04 (1.95%) | 06-12 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 2.55 | 1-year : | 2.98 |
| Resists | First : | 2.19 | Second : | 2.55 |
| Pivot price | 2.04 |
|||
| Supports | First : | 1.99 | Second : | 1.87 |
| MAs | MA(5) : | 2 |
MA(20) : | 2.02 |
| MA(100) : | 2.35 |
MA(250) : | 2.03 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 41.3 |
D(3) : | 33.8 |
| RSI | RSI(14): 54.3 |
|||
| 52-week | High : | 3.19 | Low : | 1.32 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ PLX ] has closed below upper band by 30.8%. Bollinger Bands are 57.4% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 18 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 2.11 - 2.12 | 2.12 - 2.13 |
| Low: | 2.04 - 2.05 | 2.05 - 2.06 |
| Close: | 2.07 - 2.09 | 2.09 - 2.1 |
Established in 1993 and based in Hackensack, New Jersey, Protalix BioTherapeutics, Inc. is a biopharmaceutical company primarily focused on advancing and globally commercializing recombinant therapeutic proteins. The firm utilizes its proprietary ProCellEx plant cell-based protein expression system to develop these treatments, reaching patients in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and other international regions. Protalix currently offers Elelyso, a treatment for Gaucher disease. Its robust product pipeline includes PRX-102, a therapeutic protein candidate now in late-stage clinical trials for Fabry disease. Also in development are PRX-110, a plant cell-derived recombinant human deoxyribonuclease I, which has successfully completed Phase IIa clinical trials for cystic fibrosis; PRX-115, a recombinant PEGylated Uricase expressed in plant cells for addressing gout; and PRX-119, a plant cell-expressed PEGylated recombinant human DNase I product candidate targeting NETs-related diseases. The company maintains strategic alliances and collaborations with key partners such as Pfizer, Fundação Oswaldo Cruz (Fiocruz), and Chiesi Farmaceutici S.p.A.
Thu, 14 May 2026
Protalix BioTherapeutics, Inc. (AMEX:PLX) Q1 2026 Earnings Call Transcript - Insider Monkey
Wed, 06 May 2026
Protalix BioTherapeutics to Announce First Quarter 2026 Financial Results and Business Update on May 13, 2026 - Stock Titan
Wed, 06 May 2026
Protalix BioTherapeutics to Announce First Quarter 2026 Financial Results and Business Update on May 13, 2026 - Yahoo Finance
Thu, 19 Mar 2026
Protalix BioTherapeutics (PLX) TTM Loss Challenges Bullish Profitability Narratives After FY 2025 Results - simplywall.st
Wed, 18 Mar 2026
Protalix BioTherapeutics Reports Fiscal Year 2025 Financial and Business Results - Yahoo Finance
Wed, 18 Mar 2026
Earnings call transcript: Protalix misses EPS, beats revenue in Q4 2025 - Investing.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
AMEX
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 0 (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | 0 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | 0 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | 0 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | 0 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|